XML 21 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Data
 9 Months Ended
Jun. 28, 2013
Segment Reporting [Abstract]  
Segment Data
17.
Segment Data
Selected information by business segment is as follows:

Three Months Ended

Nine Months Ended

June 28,
2013

June 29,
2012

June 28,
2013

June 29,
2012
Net sales:







Specialty Pharmaceuticals
$
308.6


$
254.7


$
913.2


$
746.3

Global Medical Imaging
247.9


246.7


706.7


754.0

Net sales of operating segments (1)
556.5


501.4


1,619.9


1,500.3

Net sales to related parties (2)
13.5


14.9


39.4


42.8

Net sales
$
570.0


$
516.3


$
1,659.3


$
1,543.1

Operating income (loss):







Specialty Pharmaceuticals
$
94.8


$
50.9


$
234.8


$
128.3

Global Medical Imaging
13.5


49.3


81.5


160.7

Segment operating income
108.3


100.2


316.3


289.0

Unallocated amounts:











Corporate and allocated expenses (3)
(43.7
)

(20.4
)

(109.4
)

(47.0
)
Intangible asset amortization
(8.9
)

(6.8
)

(26.6
)

(20.3
)
Restructuring and related charges, net (4)
(12.1
)

(6.4
)

(20.0
)

(17.3
)
Separation costs
(44.2
)

(7.2
)

(70.6
)

(17.4
)
Operating income (loss)
$
(0.6
)
 
$
59.4

 
$
89.7

 
$
187.0


(1)
Amounts represent sales to external customers. There were no intersegment sales.
(2)
Represents products that were sold to Covidien, which is discussed in note 11.
(3)
Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
(4)
Includes restructuring-related accelerated depreciation of $0.8 million and $1.4 million for the three months ended June 28, 2013 and June 29, 2012, respectively, and $2.1 million and $6.8 million for the nine months ended June 28, 2013 and June 29, 2012, respectively.